ISSN: ISSN 2472-016X

整形外科腫瘍学ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Chemotherapy's Role in Bone Cancer Treatment

Montana Mafia*

Chemotherapy plays a pivotal role in the comprehensive treatment of bone cancer, a rare and aggressive malignancy that poses significant challenges to patients and healthcare providers. As a systemic treatment, chemotherapy utilizes potent drugs to target and destroy rapidly dividing cancer cells, inhibiting tumor growth and preventing metastasis. In bone cancer treatment, chemotherapy serves multiple crucial functions, including neoadjuvant therapy to shrink tumors before surgery, adjuvant therapy to eradicate residual cancer cells post-surgery and palliative care to alleviate symptoms and improve the quality of life for advanced-stage patients. Through ongoing research and clinical advancements, chemotherapy for bone cancer has evolved, leading to more targeted and personalized therapies, thereby reducing side effects and enhancing treatment efficacy. Challenges persist; however, as bone cancer’s aggressive nature and potential drug resistance necessitate continued investigation and innovative approaches. The pursuit of further research, multidisciplinary collaboration, and precision medicine holds promise for continually refining chemotherapy’s role in bone cancer treatment, offering hope and improved outcomes for patients facing this formidable disease [1].